Search Results
Oct 20, 2025, 08:00 ET Kandu, Inc. Announces Expansion of Executive Leadership Team and Board of Directors
financial performance." "What excites me about Kandu is the combination of our team, our technology, and our ability to transform post stroke care," said Nabeel Ahmed, CFO of Kandu, Inc. "We have a world-class leadership group, a platform that meaningfully impacts patients'
More news about: Kandu, Inc.
Oct 20, 2025, 08:00 ET VantageScore Adoption Surges: Lenders Flock to Superior Predictive Capabilities Powered by Trended, Alternative Data
US market for credit cards, personal loans and auto loans. VantageScore 5.0 is the most innovative tri-bureau credit score trained and developed on post-pandemic consumer credit report data. Lenders and partners interested in converting to VantageScore models or participating in pilot programs can learn
More news about: VantageScore
Oct 20, 2025, 07:31 ET Horizon Copper Closes Arrangement with Royal Gold
for instructions and assistance in receiving the Consideration for such Horizon Shares or Horizon Warrants. While the Canada Post strike is ongoing, registered Shareholders and Warrantholders who wish to deposit their letters of transmittal, Horizon Share certificates and other
More news about: Horizon Copper Corp.
Oct 20, 2025, 07:30 ET Sandstorm Gold Royalties Closes Arrangement with Royal Gold
their intermediaries for instructions and assistance in receiving the Consideration for such Sandstorm Shares. While the Canada Post strike is ongoing, registered shareholders who wish to deposit their letters of transmittal, share certificates and other required documentation, as
More news about: Sandstorm Gold Ltd.
Oct 20, 2025, 07:30 ET Endo Launches First and Only Generic Version of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in the United States
Postmarketing Experience: The following adverse reactions have been identified during post-approval use of glycerol phenylbutyrate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible
More news about: Endo USA, Inc.
Oct 20, 2025, 07:27 ET Best Reddit Marketing Agency (Q4 2025): Nicely Network Recognized by Expert Consumers
All discussions are initiated by verified human accounts Continuous engagement and moderation maintain post credibility Live campaign reports provide transparent performance metrics
More news about: ExpertConsumers.org
Oct 20, 2025, 07:05 ET PointClickCare Announces New AI-Powered Solution and Unveils Bold New Brand, Reinforcing Commitment to Exceptional Care and Innovation
leading health tech company with one simple mission: to help providers deliver exceptional care. With the largest network of acute and long-term and post-acute care (LTPAC) data, we power AI-informed healthcare for intelligent care transitions and improved clinical outcomes that drive reimbursement. Enhanced
More news about: PointClickCare
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
across formulations (pill and injectable) in women's healthAdditional post hoc analyses from OASIS 4 and STEP phase 3a trials examined the efficacy of semaglutide in reducing body weight in women in pre- and post-menopausal stages, and another assessed improved physical function based on patient-reported
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
across formulations (pill and injectable) in women's healthAdditional post hoc analyses from OASIS 4 and STEP phase 3a trials examined the efficacy of semaglutide in reducing body weight in women in pre- and post-menopausal stages, and another assessed improved physical function based on patient-reported
More news about: NOVO NORDISK INC.
Oct 20, 2025, 06:30 ET IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
reduction in predicted radiation dose to the eye from baseline, resulting in 65% (24/37) of patients having lower predicted risk of vision loss 3-years post-PB treatment ~55% (29/53) of EN eligible and ~61% (23/38) of PB eligible patients demonstrated an improvement
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 06:00 ET Zum Recognizes School Bus Safety Week with New and Enhanced Safety Technology
All drivers are required to adhere to specific safety protocols while picking up or dropping off students and while driving, including a pre-trip and post-trip Daily Vehicle Inspection Report. Drivers are also equipped with a GPS-enabled tablet that provides real-time route updates, personalized information
More news about: Zūm
Oct 20, 2025, 06:00 ET Realtor.com®: Down Payments Steady as Average FICO Scores Remain At 10-Year High
while increasingly concentrating homebuying among higher-income households." Down Payments Remain Elevated Post-PandemicBuyers continue to put down far more cash than before the pandemic. The median down payment of $30,400 is 117.9% higher than in
More news about: Realtor.com
Oct 19, 2025, 20:15 ET CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
9-month DFS rate from surgery was 83.3%. Notably, one patient who has completed 52-week follow-up post infusion is still under follow-up without disease recurrence. Moreover, significant decline in CA19-9 levels post infusion was observed in five (83.3%) patients, with reductions ranging from 51.3% to 96.1%.
More news about: CARsgen Therapeutics
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
cohorts where the majority patients had yet to reach the protocol-specified time point of post-baseline tumor assessment: 49/72 patients underwent at least one post-baseline tumor assessment by data cutoff. Despite limited
More news about: CStone Pharmaceuticals
Oct 19, 2025, 19:30 ET IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
between structure and function in GA by analyzing ellipsoid zone (EZ) integrity and low luminance deficit (LLD) in eyes with GA treated with IZERVAY. This post hoc analysis of pooled 18-month data from the GATHER1 and GATHER2 studies demonstrated a structure-function link in GA between photoreceptor health,
More news about: Astellas Pharma Inc.
Oct 19, 2025, 09:17 ET HDAI to announce AI tools that drive quality outcomes at HLTH 2025
events before, during, after hospitalization and how leading health systems and value-based care organizations are driving down unplanned admissions, post-discharge mortality, and reducing adverse events. About Health Data Analytics Institute
More news about: Health Data Analytics Institute
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
with a peak copy number (Cmax) of 161,971 copies/μg gDNA, and copy numbers remained at 10³ by Week 8. Efficacy assessments at both Week 4 and Week 8 post-infusion showed stringent complete response (sCR), and bone marrow minimal residual disease (MRD) was negative (< 10⁻⁶) at Week 4.
More news about: CARsgen Therapeutics
Oct 18, 2025, 16:09 ET Cornerstone Capital Bank adquirirá Peoples Bank
banco comunitario líder con 13 sucursales en el oeste de Texas y el área de Dallas-Fort Worth, incluidas sucursales en Lorenzo, Lubbock, (3) Nazareth, Post, Princeton, Seminole, Seymour, Shallowater, Slaton y Whitney, con una oficina de producción de préstamos en Frisco. Peoples Bank
More news about: Cornerstone Capital Bank
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
Bradley Monk, MD, FCS medical director of late-phase clinical research, will present the following abstracts:Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 21:34 ET CVS/Aetna Medicare Advantage Plans Policy Holders Have Opportunity to Join Investigation into Improper Claim Denial for Post-Acute Care with the Schall Law Firm
determinations for post-acute care, CVS may have used artificial intelligence to vet policyholder claims prior to any evaluation by a medical professional. If you are, or were, an Aetna Medicare Advantage plan policyholder whose prior authorization request for post-acute care was
More news about: The Schall Law Firm
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
uncontrolled CRSwNP.6,7,27 Participants received tezepelumab or placebo, administered via subcutaneous injection. The trial also included a post-treatment follow-up period of 12-24 weeks for participants who completed the 52-week treatment period.6,7,27 The
More news about: Amgen
Oct 17, 2025, 14:40 ET E-Commerce Delivery Platform Veho Expands in Michigan, Ohio and North Carolina
About VehoVeho is a technology-powered e-commerce delivery platform designed for brands that care about their customers' post-purchase experience. Through its interconnected delivery network and proprietary software, Veho enables faster, more reliable, and customer-centric
More news about: Veho
Oct 17, 2025, 13:00 ET Indiegogo Launches Next-Generation Crowdfunding Platform
20+ global payment methods alongside innovative programs like Stretch Pay and Stable Pledge to make backing easier and more flexible; and Endgame, a post-campaign optimization tool that has been shown to increase average campaign funding by up to 4%. Creators can also use Follower Gifts to boost conversion
More news about: Indiegogo
Oct 17, 2025, 12:16 ET BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients
Study identified baseline clinical characteristics and those subjects with subsequent persistent post-concussive symptoms Company also announces four new U.S. patents covering
More news about: BRAINBox Solutions, Inc.
Oct 17, 2025, 12:04 ET Two Seas Capital Highlights Significant Value Upside for Core Scientific Shareholders If They Reject the Proposed Sale to CoreWeave
Core Scientific's trading price and the value of the merger consideration has resulted in a negative deal spread that has persisted since the post-IPO lock-up period on CoreWeave's stock expired on August 14. The market is clearly skeptical of this merger, and for good reason:
More news about: Two Seas Capital